Indian Marketing Company Genetic Testing Kickbacks: The Doctor’s Order Was the Product
A paid-order genetic testing kickback scheme run through an Indian marketing company allegedly drew approximately $11.5 million from Medicare. The federal criminal information alleged approximately $22.8 million in false claims for orthotic braces and cancer genetic tests. The marketer allegedly paid to obtain the orders, then received kickbacks for sending them to businesses that billed Medicare. For someone inside a call center, telemedicine company or laboratory, the revealing transaction is the payment attached to the order.
The criminal filing charged the owner of the Indian marketing company with participating in the health care fraud scheme from about February 2017 through May 2022. He later pleaded guilty to conspiring to violate the Anti-Kickback Statute and to commit health care fraud, the Department of Veterans Affairs Office of Inspector General reported in November 2023. According to the criminal information, the business bought medical authorization upstream and sold completed orders downstream. Those orders supplied the basis for Medicare claims, while kickback arrangements determined where they went.
How Paid Doctors’ Orders Reached U.S. Laboratories
The criminal information describes a chain beginning with deceptive telemarketing and ending with Medicare claims. Marketing call centers, including ones in India, allegedly obtained beneficiaries’ personal information and tricked them into accepting braces and cancer genetic tests. The marketer then paid telemedicine-company owners and executives to secure doctors’ orders regardless of medical necessity.
Those orders covered different products. The equipment side involved off-the-shelf orthotic braces, including back, knee and ankle braces. The laboratory side involved cancer genetic tests, often called CGX tests, for inherited cancer predisposition. The filing describes genetic samples typically collected with a cheek swab and sent to a laboratory for analysis. A brace supplier needed an equipment order. A genetic-testing laboratory needed a test order. According to the information, the business supplied both.
After obtaining the orders, the owner and other participants allegedly directed them to equipment and testing companies with which they had further kickback arrangements. The owner allegedly received a payment for each completed doctor’s order he steered to those businesses. The filing says the orders were then used to bill Medicare fraudulently.
That makes the marketer’s position unusually clear. He allegedly paid the businesses supplying medical orders and collected from the businesses using them. A laboratory receiving an order was at the end of a commercial arrangement that began before the specimen reached it.
The criminal information also identifies a payment moving across the border. It alleges that equipment-company operators sent approximately $32,500 from New Jersey to the owner in India in exchange for doctors’ orders.
Do Doctors Get Kickbacks for Ordering Tests?
The criminal information alleged that telemedicine companies paid healthcare providers approximately $30 per purported consultation to generate brace or cancer genetic test orders. It said those providers approved orders without establishing a doctor-patient relationship and were not treating the beneficiaries for symptoms or conditions. In that account, beneficiaries were tricked into accepting tests, doctors were paid to authorize them without treating the patients, and taxpayers picked up the bill.
The filing’s explanation of Medicare coverage shows why that mattered. The genetic test had to be ordered by a physician treating the beneficiary for a specific medical problem and using the results in managing that problem. Prosecutors alleged that the purchased orders lacked that treating relationship and produced medically unnecessary services ineligible for reimbursement.
The consultation was supposed to supply medical judgment. In the government’s account, the payment supplied an order. That is the question a telemedicine employee’s experience can illuminate: what happened between the incoming beneficiary information and the outgoing authorization, and what the provider was actually paid to do.
Marketing Invoices With a Price Per Test
The criminal information alleged that the participants disguised order payments as ordinary business expenses. It described sham agreements among marketing businesses, telemedicine companies and a laboratory that labeled kickbacks as marketing and business process outsourcing expenditures. False invoices concealed what the payments bought. Shell companies and multiple bank accounts obscured where the money came from.
One invoice episode makes the alleged arrangement concrete. In November 2021, the owner allegedly sent two sham invoices for $7,500 each, totaling $15,000. The criminal filing’s account of the invoices says they appeared to cover a mixture of marketing services but actually represented approximately $1,500 per cancer genetic test for ten tests.
The paperwork described services. The alleged payment formula counted tests. An accounts-payable employee could recognize the invoice while someone handling laboratory referrals could recognize the orders it paid for. Connecting those views explains far more than the expense description alone.
The same filing’s concealment allegations also make the intermediary businesses relevant. A payment passing through another company or bank account still has a destination and a reason. For this scheme, prosecutors alleged that the reason was obtaining and directing doctors’ orders. We examine how the contract’s stated work compares with the orders delivered and the payments made.
Why the Genetic-Testing Order Matters
The ordering relationship determines who can turn a test order into a claim. The physician documents why the patient needs the test. The laboratory receives the order, performs the work and submits its claim.
This separation has long concerned laboratory compliance specialists. Model Plan Helps Laboratories Fight Fraud, published in Laboratory Medicine in 1997, described the Inspector General’s recommendation for requisition forms with space for a physician to document the medical necessity of each test through a diagnosis code. It also described notices explaining the tests in a laboratory profile and how the laboratory would bill them.
That industry perspective explains the importance of the paid order in this case. The alleged transaction bought the document that moved a beneficiary from a marketing call toward a Medicare claim. The clinician’s role was the part the commercial arrangement needed to supply.
The Records Behind the Paid Order
For a whistleblower who knows this kind of arrangement, the connection between the order and the money is the starting point. The criminal information identifies the pieces: beneficiary information obtained through marketing, telemedicine payments, completed doctors’ orders, downstream referrals, invoices and Medicare claims. Someone who sees one part may understand a transaction that looks different elsewhere in the business.
A telemedicine employee may know how orders were approved. A laboratory employee may know which marketing source delivered them and where the clinical information came from. A finance employee may know whether an invoice followed the promised marketing work or the number of completed referrals. We work with that knowledge to connect the medical account, the billing account and the payment account.
A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers. Our work with an insider focuses on the false claims their knowledge can explain and the people and payment arrangements behind them.
You Know What the Order Bought
If you saw medical orders purchased through telemedicine or laboratory payments calculated by referral, speak with our whistleblower experts about the arrangement. We build the case around what you know, bring in laboratory fraud whistleblower lawyers who understand genetic-testing kickbacks, and stay beside you throughout your whistleblower case.
